Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.990
-0.020 (-1.00%)
At close: Oct 8, 2026, 4:00 PM EDT
1.994
+0.004 (0.19%)
After-hours: Oct 8, 2026, 7:30 PM EDT
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $11.04M in the twelve months ending June 30, 2026, up 291.42% year-over-year. In the year 2025, Pyxis Oncology had annual revenue of $13.86M, down -14.17%. That makes Pyxis Oncology the 36,848th largest company in the world by revenue and 4,847th in the United States.
Revenue (ttm)
$11.04M
Revenue Growth
+291.42%
P/S Ratio
21.54
Revenue / Employee
$197,107
Employees
56
Market Cap
237.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.86M | -2.29M | -14.17% |
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Q32 Bio | 53.74M |
| Sutro Biopharma | 45.70M |
| Zentalis Pharmaceuticals | 26.87M |
| Lineage Cell Therapeutics | 13.08M |
| Camp4 Therapeutics | 4.22M |
| Sol-Gel Technologies | 1.80M |
| Vicore Pharma Holding AB | 412.09K |
PYXS News
- 6 days ago - Pyxis Oncology announces closing of up to $282.6M public offering - TheFly
- 6 days ago - Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering - GlobeNewsWire
- 8 days ago - Pyxis Oncology 36M share Spot Secondary priced at $2.90 - TheFly
- 8 days ago - Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering - GlobeNewsWire
- 9 days ago - Pyxis Oncology announces common stock offering, no amount given - TheFly
- 9 days ago - Pyxis Oncology Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright - TheFly
- 4 weeks ago - Pyxis Oncology price target raised to $19 from $12 at Wells Fargo - TheFly